De Novo Software

De Novo Software, founded in 2000, has established itself as a critical software provider in the life sciences tools sector, with a dominant position in flow cytometry data analysis. The company's core strategy revolves around developing an integrated scientific intelligence platform that leverages AI and a familiar user interface to automate complex data workflows, thereby accelerating research and diagnostic outcomes. While not a therapeutic developer, it serves as an essential enabler for biopharma R&D, clinical labs, and academic institutions, generating revenue through software licensing. Its deep integration into high-value workflows, particularly in cell and gene therapy and clinical diagnostics, presents a stable and growing market opportunity.

Integrated scientific intelligence platform using AI for data management and workflow automation, centered on flagship flow cytometry analysis software (FCS Express) and expanded to bioinformatics, proteomics, ELN, and clinical trial design tools.

De Novo's primary competitor in flow cytometry analysis is FlowJo (acquired by BD). It also competes with analysis software bundled by instrument manufacturers (e.g., Thermo Fisher, Beckman Coulter, Cytek). In the broader scientific platform space, it faces competition from electronic lab notebook (ELN) and data analytics companies like Benchling, as well as large cloud providers offering generic data science tools.